Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Morgan Stanley Upgrades Halozyme Therapeutics to Overweight, Raises Price Target to $75

Author: Benzinga Newsdesk | August 06, 2025 06:19am
Morgan Stanley analyst Vikram Purohit upgrades Halozyme Therapeutics (NASDAQ:HALO) from Equal-Weight to Overweight and raises the price target from $62 to $75.

Posted In: HALO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist